TLR9-Targeted STAT3 Silencing Abrogates Immunosuppressive Activity of Myeloid-Derived Suppressor Cells from Prostate Cancer Patients.

CONCLUSIONS: Overall, we demonstrate the accumulation of granulocytic MDSCs with prostate cancer progression and the feasibility of using TLR9-targeted STAT3siRNA delivery strategy to alleviate MDSC-mediated immunosuppression.
PMID: 25967142 [PubMed - as supplied by publisher]

Source: Clinical Cancer Research - May 12, 2015 Category: Cancer & Oncology Authors: Hossain DM, Pal SK, Moreira DF, Duttagupta P, Zhang Q, Won H, Jones JO, D'Apuzzo M, Forman SJ, Kortylewski M Tags: Clin Cancer Res Source Type: research